Effect of camel milk in asthmatic children: A double-blind randomized pilot study.

OBJECTIVE: Asthma is one of the prevalent diseases in children. There is some evidence regarding the benefits of camel milk in asthma. The present study was carried out to evaluate the effect of camel milk on asthmatic children. PATIENTS AND METHODS: A randomized double-blind pilot study was operated in 2018 in a tertiary center. Sixty children aged more than 6 years with not well-controlled asthma were included. The intervention was consisting of 200-ml camel milk or placebo daily for 2 months. The medication regimen and spirometry parameters were assessed before and after the intervention. Data were analyzed using SPSS software. RESULTS: A total of 57 patients completed the trial. Patients were similar in demographic and baseline characteristics (p > 0.05). There was a significant difference between groups after intervention in use of inhaled corticosteroids (96.7% vs. 70.4%, p value = 0.01), short-acting beta-agonists (53.3% vs. 29.6%, p value = 0.0001) and long-acting beta-agonists (53.3% vs. 40.7%, p value = 0.04) in control and intervention, respectively. The percent of changes in forced expiratory volume (FEV1) in the control and intervention groups was 18.54 ± 14.89 and 21.89 ± 17.83, respectively (p = 0.19). The percent of changes in FEV1/forced vital capacity (FVC) in the control and intervention groups was 8.11 ± 7.12 and 11.11 ± 8.33, respectively (p = 0.14). CONCLUSION: In our pilot study, some children with asthma may benefit from camel milk. Further studies would be useful to evaluate this hypothesis.

Efficacy and safety of oral sildenafil in cystic fibrosis children with mild to moderate lung disease.

BACKGROUND: Airway inflammation due to chronic infection is the leading cause of respiratory failure and death in most of patients with cystic fibrosis (CF). There is some evidence about anti-inflammatory activity of phosphodiesterase inhibitors in adult patients with CF. This study was designed to evaluate the efficacy, safety, and tolerability of sildenafil (a phosphodiesterase inhibitor drug) in children with CF. METHOD: This uncontrolled before-after study was conducted on 20 children with CF (mean age 14 ± 2.8 years, 50% male) with mild to moderate lung disease who were referred to CF clinic of Imam Hossein hospital in Isfahan, Iran. The patients received oral sildenafil (1 mg/kg p.o tid for 3 months). Changes in spirometric values, maximal exercise capacity, and patient-reported health by using the cystic fibrosis questionnaire-revised (CFQ-R) were evaluated before and after treatment. RESULT: CFQ-R (69.54 ± 4.6 vs 76.90 ± 5.4; P < .001) and exercise duration (401 ± 45.6 vs 497 ± 60.1 second; P < .01) increased following sildenafil therapy. In contrast, the forced expiratory value (FEV1; 84.60 ± 13.67 vs 78.40 ± 12.95; P < .001) and FEF25-75 (77.80 ± 27.33 vs 69.20 ± 21.91; P = .004) showed significant decreases. However, the mean of FEV1 /forced vital capacity did not change significantly during the study (P = .682). CONCLUSIONS: Although sildenafil can improve the quality of life and exercise capacities in CF children, it significantly decreases lung function. So, administration of this drug for CF children should be reconsidered.